Impact of manufacturer-initiated list price reduction on patient out-of-pocket costs for PCSK9 inhibitors
{{output}}
Background: Because of concerns of cost-effectiveness and low utilization, in 2018, manufacturers initiated a 60% price reduction for PCSK9 inhibitors, reducing the list price from more than $14,000 to $5,850. The goal of the red... ...
